<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01953601</url>
  </required_header>
  <id_info>
    <org_study_id>8931-019</org_study_id>
    <secondary_id>2012-005542-38</secondary_id>
    <secondary_id>142502</secondary_id>
    <secondary_id>MK-8931-019</secondary_id>
    <nct_id>NCT01953601</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)</brief_title>
  <acronym>APECS</acronym>
  <official_title>A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of two parts, Part 1 and Part 2. Part 1 assesses the efficacy and safety
      of verubecestat (MK-8931) compared with placebo administered for 104 weeks in the treatment
      of amnestic mild cognitive impairment (aMCI) due to Alzheimer's Disease (AD), also known as
      prodromal AD. Participants are randomized to receive placebo, or 12 mg or 40 mg verubecestat,
      once daily. The primary study hypothesis for Part 1 is that ≥1 verubecestat dose is superior
      to placebo with respect to the change from baseline in the Clinical Dementia Rating scale-Sum
      of Boxes (CDR-SB) score at 104 weeks. Participants completing Part 1 may choose to
      participate in Part 2, which is a long term double-blind extension to assess efficacy and
      safety of verubecestat administered for up to an additional 260 weeks. In Part 2, all
      participants receive either 12 mg or 40 mg verubecestat, once daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As a result of protocol amendment, Study Part 2 will contain a Positron Emission Tomography
      (PET) imaging substudy to assess regional neurofibrillary tangle (NFT) expression.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">November 5, 2013</start_date>
  <completion_date type="Actual">April 17, 2018</completion_date>
  <primary_completion_date type="Actual">April 17, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 (Base Study). Least Squares Mean (LSM) Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 104</measure>
    <time_frame>Baseline and Week 104 in Part 1</time_frame>
    <description>LSM change from baseline at week 104 was assessed for CDR-SB score, a clinical rating of global cognitive function, comprised of 6 domains: memory; orientation; judgment and problem solving; community affairs; home and hobbies; and personal care. For each domain, the degree of impairment is assessed by a semi-structured interview of the participant as well as the participant's caregiver. For each domain, potential scores range from 0 (no impairment) to 3 (severe impairment). Individual domain scores are summed to a total CDR-SB score (range: 0-18). Higher scores indicate more severe cognitive impairment. Further, increases in cognitive impairment would be reflected by increases in CDR-SB score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Extension Study). Mean Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 130</measure>
    <time_frame>Baseline and Week 130 (i.e., Week 26 of Part 2)</time_frame>
    <description>Mean change from baseline at week 130 was assessed for CDR-SB score, a clinical rating of global cognitive function, comprised of 6 domains: memory; orientation; judgment and problem solving; community affairs; home and hobbies; and personal care. For each domain, the degree of impairment is assessed by a semi-structured interview of the participant as well as the participant's caregiver. For each domain, potential scores range from 0 (no impairment) to 3 (severe impairment). Individual domain scores are summed to a total CDR-SB score (range: 0-18). Higher scores indicate more severe cognitive impairment. Further, increases in cognitive impairment would be reflected by increases in CDR-SB score. Per protocol, baseline refers to the baseline measurement obtained in Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 (Base Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)</measure>
    <time_frame>Up to Week 106 (up to 2 weeks following cessation of study treatment in Part 1)</time_frame>
    <description>The percentage of participants experiencing an AE in Part 1 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 (Base Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)</measure>
    <time_frame>Up to Week 104 in Part 1</time_frame>
    <description>The percentage of participants who discontinued from study drug due to an AE in Part 1 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Extension Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)</measure>
    <time_frame>From Week 104 (start of treatment in Part 2) up to Week 210 (up to 2 weeks following cessation of study treatment in Part 2)</time_frame>
    <description>The percentage of participants experiencing an AE in Part 2 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Extension Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)</measure>
    <time_frame>From Week 104 (start of treatment in Part 2) up to Week 208 (i.e., up to Week 104 in Part 2)</time_frame>
    <description>The percentage of participants who discontinued from study drug due to an AE in Part 2 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Base Study). Event-Rate Per 100 Participant Years for Progression to a Clinical Diagnosis of Probable AD Dementia</measure>
    <time_frame>Up to Week 104 in Part 1</time_frame>
    <description>The event-rate per 100 participant-years for progression to a clinical diagnosis of probable AD dementia was calculated. Adjudication of a potential case was triggered if either: 1) in the investigator's own expert judgment, they think the participant may have progressed to dementia and/or 2) the participant's CDR-SB score is ≥2 points higher compared to baseline. Cases of progression to probable AD dementia confirmed by an external adjudication committee were counted as events in the analysis. The event-rate was calculated as the number of events divided by total follow-up time (participant-years) x 100; unit of measure is event-rate / 100 participant-years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Base Study). Estimated Least Squares Mean Difference Between the Last (Week 104) and First (Week 13) Post-dose CDR-SB Assessment</measure>
    <time_frame>Week 13 and Week 104 in Part 1</time_frame>
    <description>LSM difference between weeks 104 and 13 was estimated for CDR-SB score, a clinical rating of global cognitive function, comprised of 6 domains: memory; orientation; judgment / problem solving; community affairs; home / hobbies; and personal care. For each domain, degree of impairment is scored by a semi-structured interview of the participant and the participant's caregiver (domain score range: 0 [no impairment] to 3 [severe impairment]). Domain scores sum to a total CDR-SB score (range: 0-18); higher scores indicate more severe cognitive impairment. Further, increased cognitive impairment is reflected by higher CDR-SB scores; larger differences between week 104 and week 13 scores indicates accelerated AD progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Base Study). Least Squares Mean Change From Baseline in the 3-Domain Composite Cognition Score (CCS-3D) at Week 104</measure>
    <time_frame>Baseline and Week 104 in Part 1</time_frame>
    <description>CCS-3D is composed of individual cognitive tests, grouped into 3 domains: 1) episodic memory; 2) executive function; and 3) attention/processing speed. For each cognitive test, a z-score (Z) is calculated at each time point [Z = (observed value - study population mean at baseline) / study population standard deviation at baseline]. These individual Zs are first combined into domain-specific Zs, and then into a composite Z, (i.e. CCS-3D). Theoretically, 99.9% of CCS-3D will be ± 3; more positive CCS-3D indicate greater cognitive impairment relative to the total study population at baseline. Further, negative changes in CCS-3D over time indicate improved cognition relative to the total study population at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Base Study). Least Squares Mean Percent Change From Baseline in Total Hippocampal Volume (THV) at Week 104</measure>
    <time_frame>Baseline and Week 104 in Part 1</time_frame>
    <description>Least squares mean percent change from baseline at week 104 was calculated for THV as measured by volumetric magnetic resonance imaging (vMRI). Negative percent changes from baseline indicate decreases in THV (i.e. increased hippocampal atrophy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Base Study). Least Squares Mean Change From Baseline in Composite Cortical Amyloid Standard Uptake Value Ratio (SUVR) Assessed With Amyloid Tracer [18F]Flutemetamol Using Positron Emission Tomography (PET) Imaging at Week 104</measure>
    <time_frame>Baseline and Week 104 in Part 1</time_frame>
    <description>[18F]Flutemetamol PET SUVR measures brain cortical amyloid load. The PET tracer [18F]Flutemetamol was given intravenously (IV). After 90 minutes, participants were scanned for 20 minutes. Using the PET scan images, SUVRs, the ratio of tracer signal in a specific region compared to a reference region (RR; subcortical white matter) are calculated for brain regions of interest (ROIs). SUVRs from a selected set of brain regions are averaged to compute a composite SUVR. Higher composite SUVR values indicate increased amyloid load in selected brain regions, with negative changes in composite cortical SUVR over time indicating decreases in brain amyloid load.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Base Study). Least Squares Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment Version) (ADCS-ADL MCI) Score at Week 104</measure>
    <time_frame>Baseline and Week 104 in Part 1</time_frame>
    <description>Least squares mean change from baseline at week 104 was assessed for the ADCS-ADL MCI score. The ADCS-ADL MCI is an 18-item assessment of recent, observed performance of activities of daily living administered to participants' trial partners in an interview format. For the 18 items, scores range from 0 (no independence) to (depending on the item) either 2 (5 items), 3 (9 items), or 4 (4 items), with higher scores indicating greater independence in activity performance. Scores from individual items sum to a total ADCS-ADL score (range: 0-53). Lower scores indicate less independence in activity performance and, as a result, greater AD severity. Further, increases in AD severity over time would be reflected by decreases in ADCS-ADL score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Base Study). Mean Percent Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau Concentration at Week 104</measure>
    <time_frame>Baseline and Week 104 in Part 1</time_frame>
    <description>Mean percent change from baseline at week 104 was calculated for Total Tau concentration in CSF, a measure of brain tau pathology. Per protocol, CSF Total Tau concentration was analyzed as part of a substudy in Part 1, with testing occurring only at select trial sites.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1454</enrollment>
  <condition>Amnestic Mild Cognitive Impairment</condition>
  <condition>Alzheimer's Disease</condition>
  <condition>Prodromal Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verubecestat 12 mg (Parts 1 and 2)</intervention_name>
    <description>Verubecestat 12 mg oral tablet, given once daily.</description>
    <arm_group_label>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</arm_group_label>
    <other_name>MK-8931</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verubecestat 40 mg (Parts 1 and 2)</intervention_name>
    <description>Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.</description>
    <arm_group_label>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</arm_group_label>
    <arm_group_label>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</arm_group_label>
    <other_name>MK-8931</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Part 1)</intervention_name>
    <description>Placebo matching verubecestat, given once daily as an oral tablet.</description>
    <arm_group_label>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of prodromal AD, including the following:

               1. History of subjective memory decline with gradual onset and slow progression for
                  at least one year corroborated by an informant,

               2. Objective impairment in episodic memory by memory test performed at Screening,

               3. Does not meet criteria for dementia, AND

               4. Positive Screening amyloid imaging PET scan using [18F]flutametamol tracer or
                  positive Screening CSF tau:amyloid─β42 (Aβ42) ratio (Participants with a prior
                  positive amyloid imaging PET scan or a Screening PET scan with florbetaben or
                  florbetapir may be enrolled without a Screening flutemetamol scan with Sponsor
                  approval)

          2. Able to read at a 6th grade level or equivalent

          3. If participant is receiving an acetylcholinesterase inhibitor or memantine, the dose
             must have been stable for at least three months before Screening

          4. Must have a reliable and competent trial partner/informant who has a close
             relationship with the participant and is willing to accompany the participant to all
             required trial visits, and to monitor compliance of the administration of the trial
             medication

        Inclusion Criteria for Extension Period (Part 2):

          1. Tolerated study drug and completed the initial 104─week period of the trial (Part 1)

          2. Participant must have a reliable and competent trial partner who must have a close
             relationship with the subject

        Exclusion Criteria:

          1. History of stroke

          2. Evidence of a clinically relevant neurological disorder other than the disease being
             studied (i.e., prodromal AD)

          3. History of seizures or epilepsy within the last 5 years

          4. Evidence of a clinically relevant or unstable psychiatric disorder, excluding major
             depression in remission

          5. Participant is at imminent risk of self─harm or of harm to others

          6. History of alcoholism or drug dependency/abuse within the last 5 years before
             Screening

          7. Participant does not have a magnetic resonance imaging (MRI) scan obtained within 12
             months of Screening and is unwilling or not eligible to undergo an MRI scan at the
             Screening Visit. With Sponsor approval, a head computed tomography (CT) scan may be
             substituted for MRI scan to evaluate eligibility

          8. History of hepatitis or liver disease that has been active within the 6 months prior
             to Screening

          9. Recent or ongoing, uncontrolled, clinically significant medical condition within 3
             months of Screening

         10. History of malignancy occurring within the 5 years before Screening, except for
             adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,
             or localized prostate carcinoma

         11. Clinically significant vitamin B12 or folate deficiency in the 6 months before
             Screening

         12. Use of any investigational drugs or participation in clinical trials within the 30
             days before Screening

         13. History of a hypersensitivity reaction to more than three drugs

         14. Has human immunodeficiency virus (HIV) by medical history

         15. Participant is unwilling or has a contraindication to undergo PET scanning including
             but not limited to claustrophobia, excessive weight or girth

         16. History or current evidence of long QT syndrome, corrected QT (QTc) interval ≥470
             milliseconds (for male participants) or ≥480 milliseconds (for female participants),
             or torsades de pointes

         17. Close family member (including the trial partner, spouse or children) who is among the
             personnel of the investigational or sponsor staff directly involved with this trial

        Exclusion Criteria for Extension Period (Part 2):

          1. Participant is at imminent risk of self─harm or of harm to others

          2. Has developed a recent or ongoing, uncontrolled, clinically significant medical or
             psychiatric condition

          3. Results of safety assessments (e.g., laboratory tests) performed in participant at end
             of Part 1 that are clinically unacceptable to the Investigator

          4. Has developed a form of dementia that is not AD

          5. Has progressed to dementia due to AD per investigator diagnosis in the initial
             104─week study (Part 1).

        Exclusion Criteria for NFT PET Substudy (Part 2):

        1. Had one or two PET scans with MK─6240 in the initial 104─week study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 25, 2013</study_first_submitted>
  <study_first_submitted_qc>September 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2013</study_first_posted>
  <results_first_submitted>April 15, 2019</results_first_submitted>
  <results_first_submitted_qc>May 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2019</results_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT01953601/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>N=1454 participants with prodromal Alzheimer's Disease (AD) were randomized, with N=1451 receiving study treatment.</recruitment_details>
      <pre_assignment_details>This trial was conducted in 2 parts: a Base Study (Part 1), followed by an Extension Study (Part 2). Participants completing Part 1 had the option to continue to Part 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
          <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
          <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
          <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 (Base Study)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="485"/>
                <participants group_id="P2" count="484"/>
                <participants group_id="P3" count="485"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="483"/>
                <participants group_id="P2" count="484"/>
                <participants group_id="P3" count="484"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="234"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="251"/>
                <participants group_id="P2" count="253"/>
                <participants group_id="P3" count="246"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site discontinued study participation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="179"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued due to caregiver withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject moved</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2 (Extension Study)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="198">Number started refers only to participants completing Part 1, volunteering to continue to Part 2.</participants>
                <participants group_id="P2" count="191">Number started refers only to participants completing Part 1, volunteering to continue to Part 2.</participants>
                <participants group_id="P3" count="204">Number started refers only to participants completing Part 1, volunteering to continue to Part 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="191"/>
                <participants group_id="P3" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="191"/>
                <participants group_id="P3" count="204"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site discontinued study participation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="187"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued due to caregiver withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
          <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
          <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
          <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="485"/>
            <count group_id="B2" value="484"/>
            <count group_id="B3" value="485"/>
            <count group_id="B4" value="1454"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="485"/>
                    <count group_id="B2" value="484"/>
                    <count group_id="B3" value="485"/>
                    <count group_id="B4" value="1454"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.7" spread="7.1"/>
                    <measurement group_id="B2" value="71.0" spread="7.4"/>
                    <measurement group_id="B3" value="71.6" spread="7.1"/>
                    <measurement group_id="B4" value="71.4" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="485"/>
                    <count group_id="B2" value="484"/>
                    <count group_id="B3" value="485"/>
                    <count group_id="B4" value="1454"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="213"/>
                    <measurement group_id="B4" value="686"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="272"/>
                    <measurement group_id="B4" value="768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="485"/>
                    <count group_id="B2" value="484"/>
                    <count group_id="B3" value="485"/>
                    <count group_id="B4" value="1454"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="441"/>
                    <measurement group_id="B2" value="439"/>
                    <measurement group_id="B3" value="441"/>
                    <measurement group_id="B4" value="1321"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="485"/>
                    <count group_id="B2" value="484"/>
                    <count group_id="B3" value="485"/>
                    <count group_id="B4" value="1454"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="248"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="397"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="391"/>
                    <measurement group_id="B4" value="1180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Geographic Region</title>
          <population>Includes all randomized participants receiving ≥1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="483"/>
                    <count group_id="B2" value="484"/>
                    <count group_id="B3" value="484"/>
                    <count group_id="B4" value="1451"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>United States / Canada</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="226"/>
                    <measurement group_id="B4" value="676"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Japan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Europe / Australia / New Zealand</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="161"/>
                    <measurement group_id="B4" value="487"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>APOE4 Genotype</title>
          <description>Apolipoprotein E (APOE) genotype is the strongest genetic predictor of risk for developing AD. The number of participants testing positive or negative for the APOE4 allele at baseline is presented.</description>
          <population>Includes all randomized participants receiving ≥1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="483"/>
                    <count group_id="B2" value="484"/>
                    <count group_id="B3" value="484"/>
                    <count group_id="B4" value="1451"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="148"/>
                    <measurement group_id="B4" value="449"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                    <measurement group_id="B2" value="337"/>
                    <measurement group_id="B3" value="335"/>
                    <measurement group_id="B4" value="1000"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Use of Vitamin E</title>
          <description>The number of participants receiving Vitamin E (&gt; or ≤ 400 International Units [IU] / day; or no use) is presented.</description>
          <population>Includes all randomized participants receiving ≥1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="483"/>
                    <count group_id="B2" value="484"/>
                    <count group_id="B3" value="484"/>
                    <count group_id="B4" value="1451"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No Use</title>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                    <measurement group_id="B2" value="372"/>
                    <measurement group_id="B3" value="355"/>
                    <measurement group_id="B4" value="1078"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≤400 IU / day</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="343"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;400 IU / day</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Background Alzheimer's Disease (AD) Treatment</title>
          <description>The number of participants receiving acetylcholinesterase inhibitors (AChEI) and/or memantine (or no background AD treatment) is presented.</description>
          <population>Includes all randomized participants receiving ≥1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="483"/>
                    <count group_id="B2" value="484"/>
                    <count group_id="B3" value="484"/>
                    <count group_id="B4" value="1451"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Use of AChEI alone</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="180"/>
                    <measurement group_id="B4" value="553"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Use of memantine alone</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Use of AChEI and memantine</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No use of AChEI or memantine</title>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="259"/>
                    <measurement group_id="B3" value="262"/>
                    <measurement group_id="B4" value="782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini-Mental State Examination (MMSE) Score</title>
          <description>The MMSE is a cognitive assessment of 5 domains (orientation; attention; memory; language; constructional praxis), with 11 questions scored based on number of correct responses. Depending on the question, scores range from 0 (no correct response) to either 1 (4 questions), 2 (1 question), 3 (3 questions), or 5 (3 questions). Scores for each question sum to a total MMSE score (range: 0-30); lower scores indicate worse cognitive performance. Participants are stratified by MMSE score (≥24-26 or ≥27) to ensure a representative population by AD severity across study arms.</description>
          <population>Includes all randomized participants receiving ≥1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="483"/>
                    <count group_id="B2" value="484"/>
                    <count group_id="B3" value="484"/>
                    <count group_id="B4" value="1451"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>MMSE ≥27</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="214"/>
                    <measurement group_id="B4" value="637"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MMSE ≥24-26</title>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="270"/>
                    <measurement group_id="B4" value="811"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Dementia Rating Sum of Boxes (CDR-SB) Score</title>
          <description>The CDR-SB score is a clinical rating of global cognitive function, comprised of 6 domains: memory; orientation; judgment and problem solving; community affairs; home and hobbies; and personal care. For each domain, the degree of impairment is assessed by a semi-structured interview of the participant as well as the participant’s caregiver. For each domain, potential scores range from 0 (no impairment) to 3 (severe impairment). Individual domain scores are summed to a total CDR-SB score (range: 0-18). Higher scores indicate more severe cognitive impairment.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose CDR-SB observation; and 2) tested positive for cortical amyloid load by positron emission tomography (PET).</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="465"/>
                    <count group_id="B2" value="458"/>
                    <count group_id="B3" value="469"/>
                    <count group_id="B4" value="1392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="1.3"/>
                    <measurement group_id="B2" value="2.7" spread="1.3"/>
                    <measurement group_id="B3" value="2.6" spread="1.2"/>
                    <measurement group_id="B4" value="2.66" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Composite Cognition Score-3 Domain (CCS-3D)</title>
          <description>CCS-3D is composed of individual cognitive tests, grouped into 3 domains: 1) episodic memory; 2) executive function; and 3) attention/processing speed. For each cognitive test, a z-score (Z) is calculated at each time point [Z = (observed value - study population mean at baseline) / study population standard deviation at baseline]. These individual Zs are first combined into domain-specific Zs, and then into a composite Z, (i.e. CCS-3D). Theoretically, 99.9% of CCS-3D will be ± 3; more positive CCS-3D indicate greater cognitive impairment relative to the total study population at baseline.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose CCS-3D observation; and 2) tested positive for cortical amyloid load by PET.</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="441"/>
                    <count group_id="B2" value="424"/>
                    <count group_id="B3" value="440"/>
                    <count group_id="B4" value="1305"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.0" spread="1.0"/>
                    <measurement group_id="B2" value="0.0" spread="1.0"/>
                    <measurement group_id="B3" value="-0.1" spread="1.0"/>
                    <measurement group_id="B4" value="-0.01" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Hippocampal Volume (THV)</title>
          <description>THV was measured by volumetric magnetic resonance imaging (vMRI).</description>
          <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose THV observation; and 2) tested positive for cortical amyloid load by PET.</population>
          <units>µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="168"/>
                    <count group_id="B2" value="181"/>
                    <count group_id="B3" value="191"/>
                    <count group_id="B4" value="540"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6448.4" spread="1107.1"/>
                    <measurement group_id="B2" value="6468.5" spread="1105.8"/>
                    <measurement group_id="B3" value="6435.4" spread="987.2"/>
                    <measurement group_id="B4" value="6450.55" spread="1063.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>[18F]Flutemetamol Positron Emission Tomography (PET) Standard Uptake Value Ratio (SUVR)</title>
          <description>[18F]Flutemetamol PET SUVR measures brain cortical amyloid load. The PET tracer [18F]Flutemetamol was given intravenously (IV). After 90 minutes uptake, participants were scanned for 20 minutes. Using the PET scan images, SUVRs, the ratio of tracer signal in a specific region compared to a reference region (RR; subcortical white matter) are calculated for brain regions of interest (ROIs). SUVRs from a selected set of brain regions are averaged to compute a composite SUVR. Higher composite SUVR values indicate increased amyloid load in selected brain regions.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose SUVR observation; and 2) tested positive for cortical amyloid load by PET. SUVR testing occurred at select sites as a Part 1 substudy.</population>
          <units>Standard Uptake Value Ratio (SUVR)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="65"/>
                    <count group_id="B4" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.86" spread="0.07"/>
                    <measurement group_id="B2" value="0.87" spread="0.07"/>
                    <measurement group_id="B3" value="0.85" spread="0.06"/>
                    <measurement group_id="B4" value="0.86" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AD Cooperative Study-Activities of Daily Living, Mild Cognitive Impairment (ADCS-ADL MCI) Score</title>
          <description>The ADCS-ADL MCI is an 18-item assessment of recent, observed performance of activities of daily living administered to participants’ trial partners in an interview format. For the 18 items, scores range from 0 (no independence) to (depending on the item) either 2 (5 items), 3 (9 items), or 4 (4 items), with higher scores indicating greater independence in activity performance. Scores from individual items are summed for a total ADCS-ADL score (range: 0-53). Lower scores indicate less independence in activity performance and, as a result, greater AD severity.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose ADCS-ADL MCI observation; and 2) tested positive for cortical amyloid load by PET.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="469"/>
                    <count group_id="B2" value="462"/>
                    <count group_id="B3" value="472"/>
                    <count group_id="B4" value="1403"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="5.9"/>
                    <measurement group_id="B2" value="43.1" spread="5.4"/>
                    <measurement group_id="B3" value="42.8" spread="5.9"/>
                    <measurement group_id="B4" value="42.71" spread="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cerebrospinal Fluid (CSF) Total Tau Concentration</title>
          <description>Total Tau concentration in the CSF was monitored as a measure of brain tau pathology.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose observation for CSF Total Tau concentration; and 2) tested positive for cortical amyloid load by PET. CSF Total Tau concentration was analyzed at select trial sites as a Part 1 substudy.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203.8" spread="129.1"/>
                    <measurement group_id="B2" value="159.3" spread="79.0"/>
                    <measurement group_id="B3" value="243.5" spread="97.0"/>
                    <measurement group_id="B4" value="202.12" spread="101.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1 (Base Study). Least Squares Mean (LSM) Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 104</title>
        <description>LSM change from baseline at week 104 was assessed for CDR-SB score, a clinical rating of global cognitive function, comprised of 6 domains: memory; orientation; judgment and problem solving; community affairs; home and hobbies; and personal care. For each domain, the degree of impairment is assessed by a semi-structured interview of the participant as well as the participant's caregiver. For each domain, potential scores range from 0 (no impairment) to 3 (severe impairment). Individual domain scores are summed to a total CDR-SB score (range: 0-18). Higher scores indicate more severe cognitive impairment. Further, increases in cognitive impairment would be reflected by increases in CDR-SB score.</description>
        <time_frame>Baseline and Week 104 in Part 1</time_frame>
        <population>Includes all participants receiving ≥1 dose of study treatment in Part 1 who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose CDR-SB observation; and 2) tested positive for cortical amyloid load by PET.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Base Study). Least Squares Mean (LSM) Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 104</title>
          <description>LSM change from baseline at week 104 was assessed for CDR-SB score, a clinical rating of global cognitive function, comprised of 6 domains: memory; orientation; judgment and problem solving; community affairs; home and hobbies; and personal care. For each domain, the degree of impairment is assessed by a semi-structured interview of the participant as well as the participant's caregiver. For each domain, potential scores range from 0 (no impairment) to 3 (severe impairment). Individual domain scores are summed to a total CDR-SB score (range: 0-18). Higher scores indicate more severe cognitive impairment. Further, increases in cognitive impairment would be reflected by increases in CDR-SB score.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment in Part 1 who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose CDR-SB observation; and 2) tested positive for cortical amyloid load by PET.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="465"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.4" upper_limit="1.9"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.8" upper_limit="2.3"/>
                    <measurement group_id="O3" value="1.6" lower_limit="1.3" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6734</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Mean (LSM)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm A - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0141</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Means (LSM)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm B - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (Extension Study). Mean Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 130</title>
        <description>Mean change from baseline at week 130 was assessed for CDR-SB score, a clinical rating of global cognitive function, comprised of 6 domains: memory; orientation; judgment and problem solving; community affairs; home and hobbies; and personal care. For each domain, the degree of impairment is assessed by a semi-structured interview of the participant as well as the participant's caregiver. For each domain, potential scores range from 0 (no impairment) to 3 (severe impairment). Individual domain scores are summed to a total CDR-SB score (range: 0-18). Higher scores indicate more severe cognitive impairment. Further, increases in cognitive impairment would be reflected by increases in CDR-SB score. Per protocol, baseline refers to the baseline measurement obtained in Part 1.</description>
        <time_frame>Baseline and Week 130 (i.e., Week 26 of Part 2)</time_frame>
        <population>All randomized participants continuing to Part 2, with: 1) both a pre-dose baseline and ≥1 within-analysis-window, post-dose CDR-SB observation; 2) a positive test for cortical amyloid load by PET; and 3) a CDR-SB observation at week 130.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Extension Study). Mean Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 130</title>
          <description>Mean change from baseline at week 130 was assessed for CDR-SB score, a clinical rating of global cognitive function, comprised of 6 domains: memory; orientation; judgment and problem solving; community affairs; home and hobbies; and personal care. For each domain, the degree of impairment is assessed by a semi-structured interview of the participant as well as the participant's caregiver. For each domain, potential scores range from 0 (no impairment) to 3 (severe impairment). Individual domain scores are summed to a total CDR-SB score (range: 0-18). Higher scores indicate more severe cognitive impairment. Further, increases in cognitive impairment would be reflected by increases in CDR-SB score. Per protocol, baseline refers to the baseline measurement obtained in Part 1.</description>
          <population>All randomized participants continuing to Part 2, with: 1) both a pre-dose baseline and ≥1 within-analysis-window, post-dose CDR-SB observation; 2) a positive test for cortical amyloid load by PET; and 3) a CDR-SB observation at week 130.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.5"/>
                    <measurement group_id="O2" value="1.9" spread="2.2"/>
                    <measurement group_id="O3" value="1.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 (Base Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)</title>
        <description>The percentage of participants experiencing an AE in Part 1 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
        <time_frame>Up to Week 106 (up to 2 weeks following cessation of study treatment in Part 1)</time_frame>
        <population>All randomized participants in Part 1, receiving ≥1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Base Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)</title>
          <description>The percentage of participants experiencing an AE in Part 1 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
          <population>All randomized participants in Part 1, receiving ≥1 dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="484"/>
                <count group_id="O3" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3"/>
                    <measurement group_id="O2" value="92.1"/>
                    <measurement group_id="O3" value="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>4.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>8.31</ci_upper_limit>
            <estimate_desc>Difference in % = Arm A - Arm C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>5.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>9.09</ci_upper_limit>
            <estimate_desc>Difference in % = Arm B - Arm C</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1 (Base Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)</title>
        <description>The percentage of participants who discontinued from study drug due to an AE in Part 1 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
        <time_frame>Up to Week 104 in Part 1</time_frame>
        <population>All randomized participants in Part 1, receiving ≥1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Base Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)</title>
          <description>The percentage of participants who discontinued from study drug due to an AE in Part 1 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
          <population>All randomized participants in Part 1, receiving ≥1 dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="484"/>
                <count group_id="O3" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="10.1"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>2.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>5.10</ci_upper_limit>
            <estimate_desc>Difference in % = Arm A - Arm C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>5.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.35</ci_lower_limit>
            <ci_upper_limit>8.99</ci_upper_limit>
            <estimate_desc>Difference in % = Arm B - Arm C</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (Extension Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)</title>
        <description>The percentage of participants experiencing an AE in Part 2 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
        <time_frame>From Week 104 (start of treatment in Part 2) up to Week 210 (up to 2 weeks following cessation of study treatment in Part 2)</time_frame>
        <population>All randomized participants continuing to Part 2, receiving ≥1 dose of trial treatment in Part 2. For included participants, the data reflect AEs occurring in Part 2 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Extension Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)</title>
          <description>The percentage of participants experiencing an AE in Part 2 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
          <population>All randomized participants continuing to Part 2, receiving ≥1 dose of trial treatment in Part 2. For included participants, the data reflect AEs occurring in Part 2 only.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4"/>
                    <measurement group_id="O2" value="55.5"/>
                    <measurement group_id="O3" value="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>-6.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.16</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
            <estimate_desc>Difference in % = Arm A - Arm C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>-10.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.16</ci_lower_limit>
            <ci_upper_limit>-1.04</ci_upper_limit>
            <estimate_desc>Difference in % = Arm B - Arm C</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2 (Extension Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)</title>
        <description>The percentage of participants who discontinued from study drug due to an AE in Part 2 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
        <time_frame>From Week 104 (start of treatment in Part 2) up to Week 208 (i.e., up to Week 104 in Part 2)</time_frame>
        <population>All randomized participants continuing to Part 2, receiving ≥1 dose of trial treatment in Part 2. For included participants, the data reflect discontinuations occurring in Part 2 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 (Extension Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)</title>
          <description>The percentage of participants who discontinued from study drug due to an AE in Part 2 was assessed. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product is also an AE.</description>
          <population>All randomized participants continuing to Part 2, receiving ≥1 dose of trial treatment in Part 2. For included participants, the data reflect discontinuations occurring in Part 2 only.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>-2.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.03</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>Difference in % = Arm A - Arm C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>-2.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.01</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
            <estimate_desc>Difference in % = Arm B - Arm C</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Base Study). Event-Rate Per 100 Participant Years for Progression to a Clinical Diagnosis of Probable AD Dementia</title>
        <description>The event-rate per 100 participant-years for progression to a clinical diagnosis of probable AD dementia was calculated. Adjudication of a potential case was triggered if either: 1) in the investigator's own expert judgment, they think the participant may have progressed to dementia and/or 2) the participant's CDR-SB score is ≥2 points higher compared to baseline. Cases of progression to probable AD dementia confirmed by an external adjudication committee were counted as events in the analysis. The event-rate was calculated as the number of events divided by total follow-up time (participant-years) x 100; unit of measure is event-rate / 100 participant-years.</description>
        <time_frame>Up to Week 104 in Part 1</time_frame>
        <population>Includes all participants receiving ≥1 dose of study treatment in Part 1 who tested positive for cortical amyloid load by PET.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Base Study). Event-Rate Per 100 Participant Years for Progression to a Clinical Diagnosis of Probable AD Dementia</title>
          <description>The event-rate per 100 participant-years for progression to a clinical diagnosis of probable AD dementia was calculated. Adjudication of a potential case was triggered if either: 1) in the investigator's own expert judgment, they think the participant may have progressed to dementia and/or 2) the participant's CDR-SB score is ≥2 points higher compared to baseline. Cases of progression to probable AD dementia confirmed by an external adjudication committee were counted as events in the analysis. The event-rate was calculated as the number of events divided by total follow-up time (participant-years) x 100; unit of measure is event-rate / 100 participant-years.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment in Part 1 who tested positive for cortical amyloid load by PET.</population>
          <units>Event-Rate / 100 Participant-Years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5"/>
                    <measurement group_id="O2" value="25.5"/>
                    <measurement group_id="O3" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0222</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.301</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.005</ci_lower_limit>
            <ci_upper_limit>1.684</ci_upper_limit>
            <estimate_desc>HR = Arm A / Arm C</estimate_desc>
            <other_analysis_desc>Based on Cox regression model with Efron′s method of tie handling with treatment, background AD treatment (use, no use), sex, APOE4 status (carrier, non-carrier) and baseline use of Vitamin E as categorical covariates and age and baseline MMSE value as continuous covariates.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0050</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.382</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.067</ci_lower_limit>
            <ci_upper_limit>1.790</ci_upper_limit>
            <estimate_desc>HR = Arm B / Arm C</estimate_desc>
            <other_analysis_desc>Based on Cox regression model with Efron′s method of tie handling with treatment, background AD treatment (use, no use), sex, APOE4 status (carrier, non-carrier) and baseline use of Vitamin E as categorical covariates and age and baseline MMSE value as continuous covariates.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Base Study). Estimated Least Squares Mean Difference Between the Last (Week 104) and First (Week 13) Post-dose CDR-SB Assessment</title>
        <description>LSM difference between weeks 104 and 13 was estimated for CDR-SB score, a clinical rating of global cognitive function, comprised of 6 domains: memory; orientation; judgment / problem solving; community affairs; home / hobbies; and personal care. For each domain, degree of impairment is scored by a semi-structured interview of the participant and the participant's caregiver (domain score range: 0 [no impairment] to 3 [severe impairment]). Domain scores sum to a total CDR-SB score (range: 0-18); higher scores indicate more severe cognitive impairment. Further, increased cognitive impairment is reflected by higher CDR-SB scores; larger differences between week 104 and week 13 scores indicates accelerated AD progression.</description>
        <time_frame>Week 13 and Week 104 in Part 1</time_frame>
        <population>Includes all participants receiving ≥1 dose of study treatment in Part 1 who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose CDR-SB observation; and 2) tested positive for cortical amyloid load by PET.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Base Study). Estimated Least Squares Mean Difference Between the Last (Week 104) and First (Week 13) Post-dose CDR-SB Assessment</title>
          <description>LSM difference between weeks 104 and 13 was estimated for CDR-SB score, a clinical rating of global cognitive function, comprised of 6 domains: memory; orientation; judgment / problem solving; community affairs; home / hobbies; and personal care. For each domain, degree of impairment is scored by a semi-structured interview of the participant and the participant's caregiver (domain score range: 0 [no impairment] to 3 [severe impairment]). Domain scores sum to a total CDR-SB score (range: 0-18); higher scores indicate more severe cognitive impairment. Further, increased cognitive impairment is reflected by higher CDR-SB scores; larger differences between week 104 and week 13 scores indicates accelerated AD progression.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment in Part 1 who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose CDR-SB observation; and 2) tested positive for cortical amyloid load by PET.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="465"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.3" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.5" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.3" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9109</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Mean (LSM)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm A - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0824</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Mean (LSM)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm B - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Base Study). Least Squares Mean Change From Baseline in the 3-Domain Composite Cognition Score (CCS-3D) at Week 104</title>
        <description>CCS-3D is composed of individual cognitive tests, grouped into 3 domains: 1) episodic memory; 2) executive function; and 3) attention/processing speed. For each cognitive test, a z-score (Z) is calculated at each time point [Z = (observed value - study population mean at baseline) / study population standard deviation at baseline]. These individual Zs are first combined into domain-specific Zs, and then into a composite Z, (i.e. CCS-3D). Theoretically, 99.9% of CCS-3D will be ± 3; more positive CCS-3D indicate greater cognitive impairment relative to the total study population at baseline. Further, negative changes in CCS-3D over time indicate improved cognition relative to the total study population at baseline.</description>
        <time_frame>Baseline and Week 104 in Part 1</time_frame>
        <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose CCS-3D observation; and 2) tested positive for cortical amyloid load by PET.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Base Study). Least Squares Mean Change From Baseline in the 3-Domain Composite Cognition Score (CCS-3D) at Week 104</title>
          <description>CCS-3D is composed of individual cognitive tests, grouped into 3 domains: 1) episodic memory; 2) executive function; and 3) attention/processing speed. For each cognitive test, a z-score (Z) is calculated at each time point [Z = (observed value - study population mean at baseline) / study population standard deviation at baseline]. These individual Zs are first combined into domain-specific Zs, and then into a composite Z, (i.e. CCS-3D). Theoretically, 99.9% of CCS-3D will be ± 3; more positive CCS-3D indicate greater cognitive impairment relative to the total study population at baseline. Further, negative changes in CCS-3D over time indicate improved cognition relative to the total study population at baseline.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose CCS-3D observation; and 2) tested positive for cortical amyloid load by PET.</population>
          <units>Z-score</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.7" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.7" upper_limit="0.9"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0.7" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9510</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Mean (LSM)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm A - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9392</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Mean (LSM)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm B - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Base Study). Least Squares Mean Percent Change From Baseline in Total Hippocampal Volume (THV) at Week 104</title>
        <description>Least squares mean percent change from baseline at week 104 was calculated for THV as measured by volumetric magnetic resonance imaging (vMRI). Negative percent changes from baseline indicate decreases in THV (i.e. increased hippocampal atrophy).</description>
        <time_frame>Baseline and Week 104 in Part 1</time_frame>
        <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose THV observation; and 2) tested positive for cortical amyloid load by PET.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Base Study). Least Squares Mean Percent Change From Baseline in Total Hippocampal Volume (THV) at Week 104</title>
          <description>Least squares mean percent change from baseline at week 104 was calculated for THV as measured by volumetric magnetic resonance imaging (vMRI). Negative percent changes from baseline indicate decreases in THV (i.e. increased hippocampal atrophy).</description>
          <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose THV observation; and 2) tested positive for cortical amyloid load by PET.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" lower_limit="-6.9" upper_limit="-6.2"/>
                    <measurement group_id="O2" value="-6.7" lower_limit="-7.1" upper_limit="-6.3"/>
                    <measurement group_id="O3" value="-6.1" lower_limit="-6.5" upper_limit="-5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1133</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Mean (LSM)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm A - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0310</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Mean (LSM)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm B - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Base Study). Least Squares Mean Change From Baseline in Composite Cortical Amyloid Standard Uptake Value Ratio (SUVR) Assessed With Amyloid Tracer [18F]Flutemetamol Using Positron Emission Tomography (PET) Imaging at Week 104</title>
        <description>[18F]Flutemetamol PET SUVR measures brain cortical amyloid load. The PET tracer [18F]Flutemetamol was given intravenously (IV). After 90 minutes, participants were scanned for 20 minutes. Using the PET scan images, SUVRs, the ratio of tracer signal in a specific region compared to a reference region (RR; subcortical white matter) are calculated for brain regions of interest (ROIs). SUVRs from a selected set of brain regions are averaged to compute a composite SUVR. Higher composite SUVR values indicate increased amyloid load in selected brain regions, with negative changes in composite cortical SUVR over time indicating decreases in brain amyloid load.</description>
        <time_frame>Baseline and Week 104 in Part 1</time_frame>
        <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose SUVR observation; and 2) tested positive for cortical amyloid load by PET.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Base Study). Least Squares Mean Change From Baseline in Composite Cortical Amyloid Standard Uptake Value Ratio (SUVR) Assessed With Amyloid Tracer [18F]Flutemetamol Using Positron Emission Tomography (PET) Imaging at Week 104</title>
          <description>[18F]Flutemetamol PET SUVR measures brain cortical amyloid load. The PET tracer [18F]Flutemetamol was given intravenously (IV). After 90 minutes, participants were scanned for 20 minutes. Using the PET scan images, SUVRs, the ratio of tracer signal in a specific region compared to a reference region (RR; subcortical white matter) are calculated for brain regions of interest (ROIs). SUVRs from a selected set of brain regions are averaged to compute a composite SUVR. Higher composite SUVR values indicate increased amyloid load in selected brain regions, with negative changes in composite cortical SUVR over time indicating decreases in brain amyloid load.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose SUVR observation; and 2) tested positive for cortical amyloid load by PET.</population>
          <units>Standard Uptake Value Ratio (SUVR)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.04" upper_limit="-0.03"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.05" upper_limit="-0.04"/>
                    <measurement group_id="O3" value="0.02" lower_limit="0.02" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Mean (LSM)</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm A - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Mean (LSM)</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm B - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Base Study). Least Squares Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment Version) (ADCS-ADL MCI) Score at Week 104</title>
        <description>Least squares mean change from baseline at week 104 was assessed for the ADCS-ADL MCI score. The ADCS-ADL MCI is an 18-item assessment of recent, observed performance of activities of daily living administered to participants' trial partners in an interview format. For the 18 items, scores range from 0 (no independence) to (depending on the item) either 2 (5 items), 3 (9 items), or 4 (4 items), with higher scores indicating greater independence in activity performance. Scores from individual items sum to a total ADCS-ADL score (range: 0-53). Lower scores indicate less independence in activity performance and, as a result, greater AD severity. Further, increases in AD severity over time would be reflected by decreases in ADCS-ADL score.</description>
        <time_frame>Baseline and Week 104 in Part 1</time_frame>
        <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose ADCS-ADL MCI observation; and 2) tested positive for cortical amyloid load by PET.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Base Study). Least Squares Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment Version) (ADCS-ADL MCI) Score at Week 104</title>
          <description>Least squares mean change from baseline at week 104 was assessed for the ADCS-ADL MCI score. The ADCS-ADL MCI is an 18-item assessment of recent, observed performance of activities of daily living administered to participants' trial partners in an interview format. For the 18 items, scores range from 0 (no independence) to (depending on the item) either 2 (5 items), 3 (9 items), or 4 (4 items), with higher scores indicating greater independence in activity performance. Scores from individual items sum to a total ADCS-ADL score (range: 0-53). Lower scores indicate less independence in activity performance and, as a result, greater AD severity. Further, increases in AD severity over time would be reflected by decreases in ADCS-ADL score.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose ADCS-ADL MCI observation; and 2) tested positive for cortical amyloid load by PET.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="469"/>
                <count group_id="O2" value="462"/>
                <count group_id="O3" value="472"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" lower_limit="-6.1" upper_limit="-4.3"/>
                    <measurement group_id="O2" value="-5.8" lower_limit="-6.8" upper_limit="-4.8"/>
                    <measurement group_id="O3" value="-4.1" lower_limit="-5.0" upper_limit="-3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0960</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Mean (LSM)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm A - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0110</p_value>
            <method>Longitudinal ANCOVA</method>
            <param_type>Difference in Least Squares Mean (LSM)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>97.51</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>Difference in LSM = Arm B - Arm C</estimate_desc>
            <other_analysis_desc>Analysis model includes categorical factors of geographic region, time, treatment, gender, APOE genotype, baseline use of Vitamin E, baseline use of AChEI, and the interaction of time by treatment, with baseline value, the interaction of baseline value and time, the baseline value of MMSE and the baseline value of age included as continuous covariates.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1 (Base Study). Mean Percent Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau Concentration at Week 104</title>
        <description>Mean percent change from baseline at week 104 was calculated for Total Tau concentration in CSF, a measure of brain tau pathology. Per protocol, CSF Total Tau concentration was analyzed as part of a substudy in Part 1, with testing occurring only at select trial sites.</description>
        <time_frame>Baseline and Week 104 in Part 1</time_frame>
        <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose observation for CSF Total Tau concentration; and 2) tested positive for cortical amyloid load by PET. CSF Total Tau concentration was analyzed at select trial sites as a Part 1 substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)</title>
            <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)</title>
            <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1 (Base Study). Mean Percent Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau Concentration at Week 104</title>
          <description>Mean percent change from baseline at week 104 was calculated for Total Tau concentration in CSF, a measure of brain tau pathology. Per protocol, CSF Total Tau concentration was analyzed as part of a substudy in Part 1, with testing occurring only at select trial sites.</description>
          <population>Includes all participants receiving ≥1 dose of study treatment who: 1) had both a pre-dose baseline and ≥1 within-analysis-window, post-dose observation for CSF Total Tau concentration; and 2) tested positive for cortical amyloid load by PET. CSF Total Tau concentration was analyzed at select trial sites as a Part 1 substudy.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="44.3"/>
                    <measurement group_id="O2" value="42.8" spread="39.7"/>
                    <measurement group_id="O3" value="10.2" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>[Part 1]: Up to Week 106 of Part 1 (up to 2 weeks following cessation of study treatment in Part 1); [Part 2]: From Week 104 (start of treatment in Part 2) up to Week 210 (up to 2 weeks following cessation of study treatment in Part 2).</time_frame>
      <desc>[Part 1] Includes all randomized participants in Part 1 (Base Study) receiving ≥1 dose of study treatment. [Part 2] Includes all randomized participants continuing to Part 2 (Extension Study) receiving ≥1 dose of study treatment in Part 2. For Part 2-specific arms, only the AEs occurring during Part 2 are reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A. Verubecestat 12 mg (Part 1)</title>
          <description>[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study).</description>
        </group>
        <group group_id="E2">
          <title>Arm B. Verubecestat 40 mg (Part 1)</title>
          <description>[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study).</description>
        </group>
        <group group_id="E3">
          <title>Arm C. Placebo (Part 1)</title>
          <description>[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study).</description>
        </group>
        <group group_id="E4">
          <title>Arm A. Verubecestat 12 mg (Part 2)</title>
          <description>[Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 12 mg once daily for an additional 260 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Arm B. Verubecestat 40 mg (Part 2)</title>
          <description>[Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Arm C. Verubecestat 40 mg (Part 2)</title>
          <description>[Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive verubecestat 40 mg once daily for an additional 260 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="484"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="191"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Angina pectoris aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation with rapid ventricular response</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Coronary artery disease aggravated</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Non ST segment elevation myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Paroxysmal supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Recurrent atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ventricular bigeminy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Right coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchogenic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Benign paroxysmal positional vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cataract bilateral NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Right cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Acute enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastrointestinal upset</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Haemorrhoids aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Indirect inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Left inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Left upper quadrant pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Right inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tenderness epigastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Diverticular disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pyloric ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Acute chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Chest pain aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Chest pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Fever of unknown origin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gait abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Acute diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bacillus bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bacterial parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cellulitis of foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cellulitis of hand</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cellulitis of leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Influenza B virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Prosthesis related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Septic arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Spinal cord infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Viral syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bacterial prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Influenza A virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol intoxication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Arm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bimalleolar fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bruise of head</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Chronic subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Finger injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Fracture of intertrochanteric section of femur, closed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Fractured mandible</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Joint ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lumbar spine compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Olecranon fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pain trauma activated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Post procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Postoperative haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Postoperative hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Subarachnoid bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Subdural haematoma (traumatic)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture T12</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Trochanteric femoral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Faecal occult blood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hyponatraemia aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cervical spondylosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Coxarthrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Herniated disc</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Herniated nucleus pulposus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hips osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Knee osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lumbar disc herniation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Osteoarthritis aggravated</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Rotator cuff tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Spinal stenosis NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Back muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of prostate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Atypical fibroxanthoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="483"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="484"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="484"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="197"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Carcinoma in situ of breast ductal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cervical cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Colonic tubular adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lentigo melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lip basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Melanoma in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Nodular basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pancreas cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Prostate carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Skin carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of head and neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="484"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin in situ</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin well differentiated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the nasal cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Superficial basal cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urothelial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dementia aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Epileptic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Felt faint</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Neurocardiogenic syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Nonconvulsive status epilepticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Syncopal attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Transient cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tremor aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Unconsciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Neurologic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Acute mania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Confusion aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Psychosis aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Psychotic episode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Somatisation disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Unsuccessful suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Acute delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Calculus renal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Stone urinary bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ureteral stricture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin's cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Benign prostatic hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urogenital prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Collapse of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pharyngeal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exanthem</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urticarial rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hypertensive episode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Peripheral obliterative arteriopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="202" subjects_at_risk="484"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="191"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="35" subjects_affected="28" subjects_at_risk="483"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="484"/>
                <counts group_id="E3" events="38" subjects_affected="36" subjects_at_risk="484"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="197"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="483"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="484"/>
                <counts group_id="E3" events="34" subjects_affected="24" subjects_at_risk="484"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Common cold syndrome</sub_title>
                <counts group_id="E1" events="33" subjects_affected="22" subjects_at_risk="483"/>
                <counts group_id="E2" events="48" subjects_affected="32" subjects_at_risk="484"/>
                <counts group_id="E3" events="38" subjects_affected="26" subjects_at_risk="484"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="197"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="37" subjects_affected="31" subjects_at_risk="483"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="484"/>
                <counts group_id="E3" events="38" subjects_affected="31" subjects_at_risk="484"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="37" subjects_affected="30" subjects_at_risk="483"/>
                <counts group_id="E2" events="35" subjects_affected="26" subjects_at_risk="484"/>
                <counts group_id="E3" events="30" subjects_affected="23" subjects_at_risk="484"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E6" events="10" subjects_affected="8" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="56" subjects_affected="42" subjects_at_risk="483"/>
                <counts group_id="E2" events="48" subjects_affected="36" subjects_at_risk="484"/>
                <counts group_id="E3" events="41" subjects_affected="33" subjects_at_risk="484"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="197"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="483"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="484"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="484"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="49" subjects_affected="37" subjects_at_risk="483"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="484"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="484"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="197"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="483"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="484"/>
                <counts group_id="E3" events="28" subjects_affected="24" subjects_at_risk="484"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="483"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="484"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="484"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="48" subjects_affected="31" subjects_at_risk="483"/>
                <counts group_id="E2" events="50" subjects_affected="40" subjects_at_risk="484"/>
                <counts group_id="E3" events="26" subjects_affected="25" subjects_at_risk="484"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="197"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

